Verici Dx (LON:VRCI) Shares Down 4.8% – What’s Next?

Verici Dx plc (LON:VRCI)’s stock price fell 4.8% during trading on Thursday . The company traded as low as GBX 0.50 and last traded at GBX 0.50. 98,999 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 1,737,065 shares. The stock had previously closed at GBX 0.53.

Verici Dx Price Performance

The firm has a market capitalization of £7.57 million, a price-to-earnings ratio of -0.17 and a beta of 1.40. The business’s fifty day simple moving average is GBX 0.54 and its 200 day simple moving average is GBX 0.68. The company has a debt-to-equity ratio of 11.36, a current ratio of 0.91 and a quick ratio of 8.49.

Verici Dx Company Profile

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.